Study of 1,5-Anhydroglucitol as a Marker of Beta-Cell Function in Children Ages 2 to 18 With Type 1 Diabetes

What this Trial Is About

Researchers are investigating the blood levels of 1,5-anhydroglucitol 1,5-AG in children with type 1 diabetes to see how these levels relate to the function and mass of insulin-producing beta cells. This study includes children newly diagnosed with diabetes as well as those with longstanding disease, comparing their results to healthy volunteers. The goal is to evaluate 1,5-AG as a new biomarker for assessing beta-cell health in type 1 diabetes. The study involves measuring 1,5-AG levels in groups of children aged 2 to 18 years. For newly diagnosed patients, measurements will be taken at diagnosis, then again four months and one year later. For children with longer disease duration, groups with 3, 5, and 10 years of diabetes will be assessed. These prospective measurements aim to track changes in beta-cell function over time. Participants will have blood tests at the specified time points to measure 1,5-AG and compare it with indirect markers of beta-cell function and mass. Data will be collected in a one-center setting, with children monitored using continuous or flash glucose monitoring systems. The study will evaluate correlations at diagnosis and during follow-up, helping to explore the potential of 1,5-AG as a biomarker in diabetes management.

Anhydroglucitol in Children With Type 1 Diabetes